Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

e 30, of U.S.$) 2009 2008 2009 2008 -------------------- --------------------------- ------------------------ Net (loss) income on a GAAP basis $ (11,877) (26,071) $ 567 $ (41,834) Interest expense on long-term debt 9,641 10,941 19,685 23,061 Income tax (recovery) expense (217) (1,988) 5,507 (5,802) Depreciation and amortization 9,207 9,723 18,368 19,172 -------------------- --------------------------- ------------------------ EBITDA 6,754 (7,395) 44,127 (5,403) Adjustments: Non-recurring revenue, net of license fees (398) (53) (25,451) (106) Abnormal manufacturing variances and inventory write-downs 896 - 896 - In-process research and development - - - 2,500 Non-recurring research and development 625 - 938 625 Stock-based compensation 423 607 807 1,425 Litigation expenses 1,494 691 2,241 2,289 Foreign exchange loss (gain) 1,441 (140) 709 (563) Investment and other income 600 (686) 615 (1,442) Severance and restructuring 332 1,762 1,266 4,840 Write off of capitalized costs - 500 - 500 Write-down / loss on redemption of investments - 10,660 - 10,660 Non-recurring financing costs 413 - 1,032 - --
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... LAGUNA HILLS, Calif., Sept. 4 CODA Genomics, ... Optimized DNA,Assembly) towards the manufacture of synthetic genes ... Patent and Trademark Office has,issued US Patent 7,262,031 ... (UCI) professors, Richard H. Lathrop and G. Wesley,Hatfield. ...
... Sept. 4 Volcano,Corporation (Nasdaq: VOLC ), ... (FM) products designed to enhance the diagnosis,and treatment ... that it,will be participating in the Bear Stearns ... presentation by Scott Huennekens, president and chief executive,officer, ...
... (Nasdaq: ALXN ) today announced that Dr. Leonard ... the,Bear Stearns 20th Annual Healthcare Conference in New York ... An audio webcast of Dr. Bell,s remarks will ... http://www.alexionpharm.com . An archived version of the,remarks will also ...
Cached Biology Technology:CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent 2Volcano Corporation Presentation at Bear Stearns Conference to be Webcast 2
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... issue of Nature Methods Shows Application of Bioinformatics ... ... GENEVA, Switzerland, Aug. 21 Researchers at Selexis SA,and ... novel,high-performance Genetic Elements also known as matrix attachment regions,(or ...
... know that not all plants from the same species ... that not only prevent the exchange of genes between ... a species), but also between varieties of one and ... central importance if one wants to understand the origin ...
... Europe, which many archaeologists believed to be descended from ... East by Stone Age farmers, new research suggests. ... at Durham University, which is published today in the ... USA, analysed mitochondrial DNA from ancient and modern pig ...
Cached Biology News:Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines 2How the plant immune system can drive the formation of new species 2How the plant immune system can drive the formation of new species 3Pig study sheds new light on the colonisation of Europe by early farmers 2
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... A number of modifications of Grace's ... the late 1960's and 1970's. Many of ... Hink for the growth of cells derived ... represents the modification known as TNM-FH. The ...
... GST•Tag™ Ek Adaptor encodes a T7 promoter, ... (rbs), ATG translation initation codon and an ... has been reported to enhance the production ... its fusion partners. The GST•Tag is a ...
...
Biology Products: